Context
Asymptomatic middle-aged adult children of patients with Alzheimer disease (AD) recently were found to exhibit functional magnetic resonance imaging (fMRI) deficits in the mesial temporal lobe during an encoding task. Whether this effect will be observed on other fMRI tasks is yet unknown. This study examines the neural substrates of self-appraisal (SA) in persons at risk for AD. Accurate appraisal of deficits is a problem for many patients with AD, and prior fMRI studies of healthy young adults indicate that brain areas vulnerable to AD such as the anterior mesial temporal lobe and posterior cingulate are involved during SA tasks.
Objective
To determine whether parental family history of AD (hereafter referred to as FH) or presence of the ε4 allele of the apolipoprotein E gene (APOE4) exerts independent effects on brain function during SA.
Design
Cross-sectional factorial design in which APOE4 status (present vs absent) was one factor and FH was the other. All participants received cognitive testing, genotyping, and an fMRI task that required subjective SA decisions regarding trait adjective words in comparison with semantic decisions about the same words.
Setting
An academic medical center with a research-dedicated 3.0-T MR imaging facility.
Participants
Cognitively normal middle-aged adults (n = 110), 51 with an FH and 59 without an FH.
Main Outcome Measure
Blood oxygen–dependent contrast measured using T2*-weighted echo-planar imaging.
Results
Parental family history of AD and APOE4 status interacted in the posterior cingulate and left superior and medial frontal regions. There were main effects of FH (FH negative > FH positive) in the left hippocampus and ventral posterior cingulate. There were no main effects of APOE genotype.
Conclusions
Our results suggest that FH may affect brain function during subjective SA in regions commonly affected by AD. Although the participants in this study were asymptomatic and middle-aged, the findings suggest that there may be subtle alterations in brain function attributable to AD risk factors.
Neuropathological studies1-4 of persons at risk for Alzheimer disease (AD) suggest that AD may be preceded by a silent preclinical phase in which the brain incurs neuropathological change. Presence of the ε4 allele of the apolipoprotein E gene (APOE4) and parental family history of AD (hereafter referred to as FH)5 are risk factors for developing late-onset AD.6 Identifying initial brain changes in at-risk individuals using noninvasive functional imaging may help elucidate preclinical presence and progression of early AD.
Most prior functional magnetic resonance imaging (fMRI) studies7-15 in populations at risk for AD have focused on the hippocampus using episodic memory tasks that draw on encoding or retrieval processes because memory symptoms are among the earliest to occur in AD. It has recently been shown that asymptomatic middle-aged adults (mean age, 55 years) who have a parent with AD exhibit reduced blood oxygenation level–dependent (BOLD) responses in the mesial and ventral temporal lobes during an encoding task,12 and this effect was not explained by APOE genotype. The findings suggest that memory-related brain changes attributable to FH may be occurring in regions vulnerable to AD approximately 2 decades before the typical age at onset in sporadic AD.
Other early symptoms of AD may involve high-level executive functions such as metacognitive appraisal. Studies on executive functions have often operationalized the construct to the cognitive control processes that subserve executive function, including working memory, mental flexibility and speed, imperviousness to distraction, and inhibition of prepotent responses. These well-studied functions have generally been attributed to the dorsolateral prefrontal cortex.16 The metacognitive aspects of executive function are less well studied and include processes such as self-monitoring, planning prospective action, making inferential or subjective decisions, self-appraisal (SA) (the focus of the present study), and social tuning of one's behavior for adaptive functioning in the world of people (judgment).
Prior studies have implicated cortical midline structures, including the anterior medial prefrontal cortex and posterior cingulate for metacognitive processes,17-19 particularly the processes of self-regulation of affect, self-reflection on abilities and traits, self-monitoring of actions and bodily states, and social cognition such as making inferences about the mental states of others.20 The hippocampus has also been implicated in cognitive SA.21 Neuroimaging studies of the posterior cingulate have found a decreased cerebral metabolic rate of glucose metabolism,22-24 cerebral atrophy,22,25 and amyloid binding22,26 in persons with AD. In 2 studies,4,24 subjects at risk for AD also exhibited reductions in cerebral metabolic rate of glucose in the posterior cingulate. Furthermore, “resting state” abnormalities in AD have been found in the posterior cingulate and medial frontal lobes, as well as the hippocampus.22,27,28
No studies have yet examined metacognitive brain function in healthy persons at risk for AD, to our knowledge. This may be a useful avenue of study because patients with AD often exhibit deficits in metacognitive abilities29 such as appreciating the extent or severity of their deficits. The objective of the present study was to determine whether we could observe AD risk–associated differences in BOLD activity during a self-referential decision task that consistently evokes BOLD activity from the posterior cingulate, medial frontal lobe, and mesial temporal lobes across prior studies19,30-32 of healthy adults. We examined brain activation in 110 physically and cognitively asymptomatic middle-aged adults who differed in FH and APOE4 status. A 2 × 2 factorial design was used to examine the relative contribution of APOE genotype and FH on the cerebral response. Based on prior findings, we expected that FH would have an effect on cerebral activation that was separable from APOE genotype in cortical midline brain regions and hippocampus.
One hundred ten subjects underwent fMRI and cognitive testing (Table 1). Fifty-one (mean ± SD age, 53.6 ± 6.4 years) had at least 1 parent with AD (FH positive) and were recruited from the Wisconsin Registry for Alzheimer's Prevention,33 a longitudinal registry of cognitively normal adults between the ages of 40 and 65 years (at enrollment) who have at least 1 parent with sporadic AD. To verify the diagnosis of AD in the parent, parental medical records were obtained and were reviewed by a multidisciplinary diagnostic consensus panel. Typically, the clinical workup and diagnosis in the parent were conducted at the University of Wisconsin Memory Clinics, and the adult children were then approached for participation. The mean age at symptom onset in the affected parent was 73 years. All subjects in the FH-positive group underwent baseline neuropsychological evaluations and laboratory tests that included APOE genotyping using polymerase chain reaction and sequencing. Fifty-three percent (27 of 51) were ε4 positive (ε3/ε3, 24 subjects; ε3/ε4, 20 subjects; and ε4/ε4, 7 subjects).
Fifty-nine participants (mean ± SD age, 55.3 ± 6.2 years) with no FH (FH negative) were recruited from the community and were matched to the demographic characteristics of the FH-positive sample. Absence of FH was determined through self-report of the participant by telephone interview and by detailed medical history questionnaire. To be included in the FH-negative group, both parents had to survive to at least age 70 years (most were well beyond this age) and not have a diagnosis of dementia or exhibit frank symptoms of dementia of any kind. Twelve control subjects (20%) were ε4 positive (ε3/ε4, 11 subjects; and ε4/ε4, 1 subject), and 47 were ε4 negative (all ε3/ε3).
The demographics of the ε4-positive and ε4-negative subgroups are given in Table 1, along with neuropsychological and fMRI task performance. We only included participants who had the ε4 or ε3 allele of APOE (21 participants with ε2 alleles were excluded). This was done to control for potential heterogeneity among genotypes. The proportion of women in the cells differed; therefore, sex was used as a covariate in the fMRI data analysis. Exclusions for this imaging study included MR imaging scanner incompatibility, abnormal structural MR imaging or neuropsychological test results as part of study participation, or history of major psychiatric disease (eg, schizophrenia, substance dependence, and current or recent major depression) or major medical conditions (eg, type 1 diabetes mellitus, cancer requiring chemotherapy or radiation therapy, and neurological disorders, including prior head trauma with loss of consciousness). Most patients taking psychoactive drugs were excluded, although we allowed low-dose selective serotonin reuptake inhibitors if the patient had been stable for more than 3 months.
All subjects in the study received an additional fMRI task of episodic encoding that has been reported on previously.12 Participation in this study was contingent on signed informed consent, and the study was conducted in accord with the Declaration of Helsinki.
The fMRI paradigm has been described in detail in prior studies of healthy young adults30 and subjects with mild cognitive impairment (MCI).34 Briefly, the task requires participants to make yes or no decisions based on individually presented trait adjectives across 2 conditions, referential SA and nonreferential affective or semantic decision (SEM). The same set of 30 adjectives was presented in the SA and SEM conditions in counterbalanced order. In the SA condition, participants decided whether or not adjectives described their personal traits and abilities, whereas in the SEM condition, they decided whether or not adjectives in the set were of positive valence. The first presentation of each adjective was counterbalanced across conditions such that novelty was not confounded with condition order. Two equivalent forms of the task were presented sequentially (counterbalanced), each using separate adjective sets. Within each task run, each of the 2 conditions was presented in 5 pseudorandomized cycles. Words were presented every 4 seconds (3 seconds on screen and a 1-second interstimulus interval) in blocks of 6 per condition.
After higher-order shimming, T2*-weighted gradient-echo echo-planar images were obtained as follows: echo time, 30 milliseconds; repetition time (TR), 2000 milliseconds; flip angle, 90°; acquisition matrix, 64 × 64 voxels; and field of view, 240 mm. Thirty sagittal sections of the brain were acquired within the TR at each time point, with voxel resolution of 3.75 × 3.75 × 4 mm and 1-mm skip between sections. In 4-minute and 8-second imaging trials, 124 time points were collected, of which 3 images acquired during the first 6 seconds were discarded (for a total of 242 reconstructed time points).
Residual magnetic field inhomogeneity resulting in regional distortions are common with echo-planar images. We corrected these by measuring 3-dimensional field maps across the brain (coplanar with the fMRI sections). This was accomplished by measuring the phase of non–echo-planar image gradient-echo images at 2 echo times (7 milliseconds and 10 milliseconds). The phase difference between the 2 echo images is proportional to the static field inhomogeneity.35 The warp calculation and correction36 were performed using the FMRIB Software Library version FSL3.2 (http://www.fmrib.ox.ac.uk/fsl). Anatomical T1-weighted volumes and T2-weighted axial seconds were also acquired using parameters previously described.12
For anatomical imaging and voxel-based morphometry analysis, axial T1-weighted and T2-weighted images were acquired after the functional runs. A 3-dimensional inversion recovery– prepared fast gradient echo–pulse sequence provided high-resolution T1-weighted structural images with the following parameters: inversion time, 600 milliseconds, fast gradient echo–pulse readout with TR/echo time/flip angle, 9 milliseconds/1.8 milliseconds/20°; acquisition matrix, 256 × 192 × 124 voxels (interpolated to 256 × 256 × 124 voxels); field of view, 240 mm; section thickness, 1.2 mm (124 sections); and ±160-kHz receiver bandwidth.
A fast-recovery fast spin-echo 2-dimensional T2-weighted axial sequence was also acquired with the same start and stop locations as the T1-weighted images. The parameters were as follows: field of view, 240 mm; acquisition matrix, 256 × 256 voxels; TR, 9000 milliseconds; echo time, 93 milliseconds; and flip angle, 90°. Seventy sections were acquired; the section thickness was 1.7 mm with a 0.3-mm skip. An experienced neuroradiologist (H.A.R.) examined all of the images before the analysis for clinical evidence of any neurovascular disease or structural abnormality that would exclude the subjects from the analysis.
Other preprocessing steps and statistical analysis were performed using Statistical Parametric Mapping SPM2 software (http://www.fil.ion.ucl.ac.uk/spm). The image time series was motion corrected, field map corrected as already described, normalized into the Montreal Neurological Institute standard space using the T2-weighted template provided through SPM2 (written out with 2 × 2 × 2-mm voxel resolution), and then smoothed with an 8-mm full-width-at-half-maximum gaussian kernel.
The time-series data for individual participants were analyzed using a boxcar model convolved with the canonical hemodynamic response function as implemented in SPM2.37 The statistical model included high-frequency signal filtering (high-pass filter, 128 seconds) and the autoregressive(1) method of estimating temporal autocorrelation. The SA vs SEM contrast was computed for each participant and was entered into second-level analyses.
The mean effect of task (SA vs SEM), collapsed across groups, was first computed and thresholded at P < .005 uncorrected, which corresponded to Pfalse discovery rate–corrected < .04. This map was written out (Figure 1 and Table 2) and was used to constrain the subsequent analyses of group differences to only those brain voxels that were relevant to the task. Using analysis of covariance (ANCOVA), a 2 × 2 factorial analysis was performed that examined between-group effects of FH, APOE genotype, and FH × APOE genotype interaction. Sex was used as a covariate. This same design was applied to the demographic and neuropsychological data. For the fMRI factorial analyses, statistical significance was also assessed at a voxel-level threshold of P < .005 uncorrected.
For anatomical analyses, to determine whether group activation differences were due to anatomical differences in gray matter volume, we conducted voxel-based morphometry in the same search space and using the same model as the fMRI ANCOVA but with the additional covariate of total gray matter volume. The procedures have been described in detail elsewhere.12,38,39
Demographic characteristics and task performance are given in Table 1. The χ2 statistic indicated that the proportion of men and women differed in 1 group; therefore, sex was used as a covariate in subsequent behavioral and fMRI ANCOVAs. Factorial ANCOVA of demographic and neuropsychological variables indicated no FH × APOE genotype interaction. Tests for main effects of APOE genotype and FH in these healthy asymptomatic subjects were also statistically nonsignificant except for Trail Making Test A, on which the ε4-negative subjects performed 3.7 seconds faster than the ε4-positive subjects. There were no differences in the fMRI behavioral data with regard to reaction time and response bias. The fMRI findings follow.
The mean response to the task (SA > SEM) is shown in Figure 1, with statistics and Montreal Neurological Institute locations given in Table 2. Active regions included 2 prominent midline clusters; the posterior cluster spans the ventral the posterior cingulate cortex, and the retrosplenial cortex.40 The large anterior medial prefrontal cortex cluster spans the medial surface of the superior frontal gyrus and rostral anterior cingulate. Also, 2 large bilateral clusters were observed in the anterior mesial temporal lobe spanning the hippocampus and amygdala and extending contiguously to the ventral forebrain and basal ganglia and thalamus. All comparisons in the subsequent factorial ANCOVA analysis were constrained to only those regions that were active in Figure 1. This procedure reduced the search region to 9.3% of the original number of voxels in the common brain mask. This was implemented to reduce the potential vulnerability to false-positive errors and to ensure that subsequent results from group comparisons were interpretable with regard to the cognitive task.
Using factorial ANCOVA, an F test for FH × APOE genotype interaction yielded prefrontal clusters at voxel location −26, 36, 36 (F = 9.73, P =.002 uncorrected; 102 voxels) in the left superior frontal gyrus and at voxel location −10, 48, 2 (F = 9.71, P =.002 uncorrected; 26 voxels) in the left anterior cingulate. A third small cluster was found in the retrosplenial area of the posterior cingulate at voxel location 0, −50, 4 (F = 8.26, P =.005 uncorrected; 33 voxels). These clusters and associated plots of signal change are shown in Figure 2. Post hoc analyses were conducted, and statistically significant mean differences are indicated on the plots. Group differences were only statistically significant relative to the FH-negative ε4-positive group. The other 3 groups did not differ from each other.
The main effects of FH and APOE genotype were tested next. Because main effects are not readily interpretable in the presence of interactions, voxels that were identified as statistically significant in the interaction map of Figure 2 were not considered in the analysis of main effects (this was achieved using the “mask with other contrasts” option in SPM2). The main effect of FH negative greater than FH positive was statistically significant in the left hippocampus (at voxel location −16, −22, −14; t = 4.05, P < .001 uncorrected; 233 voxels) and the left ventral posterior cingulate (at voxel location −14, −66, 20; t = 3.33, P = .001; 50 voxels). These results are shown in Figure 3. No statistically significant results were found in the reverse comparison (FH positive > FH negative). The effect of APOE genotype was tested using the contrast ε4 positive greater than ε4-negative (and its reverse). Statistically significant voxels in the interaction were again excluded. The results revealed no statistically significant voxels in either contrast.
Using voxel-based morphometry, no group differences in gray matter volume were found. These results suggest that the fMRI findings were not attributable to atrophy.
This study examined the cerebral response during a metacognitive task, SA on trait adjectives. We used this task in persons at risk for AD because converging research has indicated that the regions normally responsive on this task seem to overlap with brain regions affected by AD.30-32 Our analyses indicated differences in task-related activation associated with FH, as well as regions where APOE genotype and FH risk factors interacted. Parental family history of AD had the effect of diminishing the cerebral response in the ventral posterior cingulate and the left mesial temporal lobe. Although there were no main effects of APOE4 status, this risk factor interacted with FH in the left dorsolateral prefrontal cortex, anterior medial prefrontal cortex, and retrosplenial posterior cingulate; plots indicated that ε4 carriers who had no FH exhibited greater signal change to the task. The observed effects were not due to gray matter atrophy or global cognitive function.
The medial parietal cortex has been implicated in memory retrieval and recognition,22,41,42 as well as metacognitive appraisals.19,31,32,43-46 Several recent studies report medial parietal hypometabolism47 or hypoperfusion48 in individuals with MCI, a diagnosis that confers considerable risk for developing AD. Longitudinal studies49-51 also indicate that posterior cingulate metabolism and regional blood flow discriminate between individuals with MCI who soon develop AD and patients with MCI who remain stable. Reiman and colleagues4,24 found that the medial parietal lobe, including the posterior cingulate cortex and precuneus, was hypometabolic for glucose in cognitively normal APOE4 carriers relative to noncarriers (the effect of FH was not tested in these earlier studies). The medial parietal findings observed in the present study during a cognitive challenge seem to be generally consistent with these prior results and suggest that this region may be beginning to exhibit dysfunction in these asymptomatic middle-aged adults at risk for AD. As further evidence of this possibility, Ries et al34 studied amnestic patients with MCI using the same paradigm reported herein and ratings of anosognosia. A statistically significant positive correlation was found between insight and activation; subjects with MCI who exhibit diminished insight for their cognitive impairment also exhibit diminished responses in the posterior cingulate and mesial frontal lobe. The data by Ries et al34 and the findings in the present study suggest that risk factors for AD are affecting systems supporting metacognition, which may eventually become part of the symptom picture of AD.
Areas of the left medial temporal lobe were also differentially active in FH-negative subjects on this task. In a young adult sample, it was recently shown that this region of the hippocampus exhibits task-dependent functional connectivity with the anterior medial prefrontal cortex on this same task.30 The hippocampus and subiculum are densely connected to the medial frontal lobe in rhesus monkeys.52,53 Phillips et al21 include the hippocampus in the dorsal axis of an emotion appraisal model (also involving the dorsomedial and dorsolateral frontal lobe) that receives biasing self-relevant input from ventral structures, including the amygdala, nucleus accumbens, and ventral medial frontal lobe.17 Amyloid burden in the mesial temporal lobe has been found to be related to the degree of anosognosia in patients with AD.54 The role of the hippocampus in affective and cognitive appraisal and how this might relate to the symptom picture of AD is not completely understood and is deserving of much more study.
In this sample, APOE4 status and FH interacted (Figure 2), but there were no APOE4 main effects. The interaction was largely due to the finding that ε4-positive subjects but not FH-negative subjects exhibited the greatest activation. An intriguing study by Mondadori et al55 points out several salutary effects of APOE4 status on the brain in early life, and they present fMRI results of a memory encoding task indicating that young adult ε3/ε4 carriers exhibit hippocampal learning-related signal adaptation but that young noncarriers do not. There is still much to learn about the effect of APOE4 status across the life span, but in the context of the recent literature and the findings in the present study, it is likely that interactions are occurring between APOE4 status and age or other AD risk factors that manifest as a putative salutary effect early in life but as a deleterious effect later in life.
The results herein are consistent with those of a prior study12 of an episodic encoding task among most of these same subjects in which a robust effect of FH in the hippocampus and ventral temporal lobes during object encoding was found. That prior study also found that the FH-negative ε4-positive group again exhibited the greatest cerebral response in the hippocampus, while FH-positive ε4-positive subjects had the least. A similar finding was observed when subjects possessing the ε2 allele were removed.15
At least 2 other recent studies have reported FH effects. In a behavioral experiment of odor identification, it was found that siblings of patients with AD exhibited reduced accuracy relative to control subjects. This effect was more pronounced in siblings who were APOE4 positive.56 Using fMRI, Bassett et al7 examined FH and APOE genotype in a large sample (n = 195) and found that FH affected brain activation during a paired-associate encoding task but that APOE genotype did not.
There remains a fundamental issue regarding fMRI group differences in cognitively normal vs at-risk or cognitively impaired populations. Some studies have reported risk-associated8,57-59 and disease-associated10,60 increases in cerebral activity, while other studies report decreases in cerebral response with increased risk12,14,55 or cognitive impairment.13,61-63 Although there are many sources of noise and variability using fMRI, some possible reasons for these study differences are the following: (1) Increased task difficulty has the effect of increasing fMRI activation.64,65 (2) Regarding the choice of comparison condition from which BOLD signal change is measured, it has been shown that a resting low-level baseline (such as rest or crosshair fixation) and an active cognitively challenging baseline produce different results.66,67 (3) Finally, the choice of analysis methods and statistical model (eg, spatially normalizing to a standard space vs native space68 or counting of suprathreshold voxels within a region vs statistical parametric mapping) may cause difference results.10 Given the variability across studies, researchers who develop fMRI tasks for use in clinical and at-risk populations should adopt a task-specific psychometric approach to measuring brain activation. Such an approach might include parametrically varying difficulty, comparison with normative data,55 and characterization of tasks across larger samples and across a range of demographics (eg, age) and clinical parameters (eg, genes and cognitive status61).
In conclusion, these data suggest that FH may affect brain function many years before typical disease onset. The genetic and environmental factors that embody FH are still largely unknown, and further study is required. Our results highlight the idea that factors beyond APOE genotype contribute to AD and should be included when possible in studies of AD risk. Although memory dysfunction is a core feature of AD and is typically one of the first noticeable symptoms, these findings using a self-referential decision task suggest that brain areas underlying metacognitive functions may also show compromise in persons at risk and may correspond, in part, to the metacognitive deficits that are observed in symptomatic AD.
Correspondence: Sterling C. Johnson, PhD, Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terr (11G), Madison, WI 53705 (scj@medicine.wisc.edu).
Submitted for Publication: October 2, 2006; final revision received March 19, 2007; accepted March 21, 2007.
Author Contributions: Dr Johnson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This study was supported by grant R01 AG21155 (Dr Johnson) and a merit review grant from the Department of Veterans Affairs.
Additional Contributions: Britta Jabbar, BS, Shelly Fitzgerald, BS, Gemma Gliori, MS, Lisa Newman, BS, Allison Wichmann, BS, Taylor Schmitz, BS, Mehul Trivedi, PhD, Michael Anderle, BS, and Ron Fisher, BS, provided additional assistance.
1.Corder
EHGhebremedhin
ETaylor
MGThal
DROhm
TGBraak
H The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and
APOE polymorphism.
Ann N Y Acad Sci 2004;101924- 28
PubMedGoogle Scholar 2.Braak
EGriffing
KArai
KBohl
JBratzke
HBraak
H Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?
Eur Arch Psychiatry Clin Neurosci 1999;249
(Suppl 3)
14- 22
PubMedGoogle Scholar 3.Ohm
TGMüller
HBraak
HBohl
J Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease–related neurofibrillary changes.
Neuroscience 1995;64
(1)
209- 217
PubMedGoogle Scholar 4.Reiman
EMChen
KAlexander
GECaselli
RJBandy
DOsborne
DSaunders
AMHardy
J Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia [published online ahead of print December 19, 2003].
Proc Natl Acad Sci U S A 2004;101
(1)
284- 28910.1073/pnas.2635903100.
PubMedGoogle Scholar 5.Fratiglioni
LAhlbom
AViitanen
MWinblad
B Risk factors for late-onset Alzheimer's disease: a population-based, case-control study.
Ann Neurol 1993;33
(3)
258- 266
PubMedGoogle Scholar 6.Green
RCCupples
LAGo
RBenke
KSEdeki
TGriffith
PAWilliams
MHipps
YGraff-Radford
NBachman
DFarrer
LAMIRAGE Study Group, Risk of dementia among white and African American relatives of patients with Alzheimer disease.
JAMA 2002;287
(3)
329- 336
PubMedGoogle Scholar 7.Bassett
SSYousem
DMCristinzio
CKusevic
IYassa
MACaffo
BSZeger
SL Familial risk for Alzheimer's disease alters fMRI activation patterns.
Brain 2006;129
(pt 5)
1229- 1239
PubMedGoogle Scholar 8.Bondi
MWHouston
WSEyler
LTBrown
GG fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
Neurology 2005;64
(3)
501- 508
PubMedGoogle Scholar 9.Fleisher
ASHouston
WSEyler
LTFrye
SJenkins
CThal
LJBondi
MW Identification of Alzheimer disease risk by functional magnetic resonance imaging.
Arch Neurol 2005;62
(12)
1881- 1888
PubMedGoogle Scholar 10.Dickerson
BCSalat
DHGreve
DNChua
EFRand-Giovannetti
ERentz
DMBertram
LMullin
KTanzi
REBlacker
DAlbert
MSSperling
RA Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD.
Neurology 2005;65
(3)
404- 411
PubMedGoogle Scholar 11.Johnson
SCBaxter
LSusskind-Wilder
LConnor
DJSabbagh
MNCaselli
RJ Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment.
Neuropsychologia 2004;42
(7)
980- 989
PubMedGoogle Scholar 12.Johnson
SCSchmitz
TWTrivedi
MARies
MLTorgerson
BMCarlsson
CMAsthana
SHermann
BPSager
MA The influence of Alzheimer disease family history and apolipoprotein E ε4 on mesial temporal lobe activation.
J Neurosci 2006;26
(22)
6069- 6076
PubMedGoogle Scholar 13.Johnson
SCSchmitz
TWMoritz
CHMeyerand
MERowley
HAAlexander
ALHansen
KWGleason
CECarlsson
CMRies
MLAsthana
SChen
KReiman
EMAlexander
GE Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment [published online ahead of print October 13, 2005].
Neurobiol Aging 2006;27
(11)
1604- 161210.1016/j.neurobiolaging.2005.09.017
PubMedGoogle Scholar 14.Lind
JPersson
JIngvar
MLarsson
ACruts
MVan Broeckhoven
CAdolfsson
RBackman
LNilsson
LGPetersson
KMNyberg
L Reduced functional brain activity response in cognitively intact apolipoprotein E ε4 carriers [published online ahead of print March 14, 2006].
Brain 2006;129
(pt 5)
1240- 124810.1093/brain/awl054
PubMedGoogle Scholar 15.Trivedi
MASchmitz
TWRies
MLTorgerson
BMSager
MAHermann
BPAsthana
SJohnson
SC Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study.
BMC Med 2006;4e1
Google Scholar 16.Royall
DRLauterbach
ECCummings
JLReeve
ARummans
TAKaufer
DILaFrance
WCCoffey
CE Executive control function: a review of its promise and challenges for clinical research: a report from the Committee on Research of the American Neuropsychiatric Association.
J Neuropsychiatry Clin Neurosci 2002;14
(4)
377- 405
PubMedGoogle Scholar 17.Schmitz
TWJohnson
SC Relevance to self: a brief review and framework of neural systems underlying appraisal [published online ahead of print January 23, 2007].
Neurosci Biobehav Rev 2007;31
(4)
585- 59610.1016/j.neubiorev.2006.12.003
PubMedGoogle Scholar 18.Northoff
GBermpohl
F Cortical midline structures and the self.
Trends Cogn Sci 2004;8
(3)
102- 107
PubMedGoogle Scholar 19.Northoff
GHeinzel
Ade Greck
MBermpohl
FDobrowolny
HPanksepp
J Self-referential processing in our brain: a meta-analysis of imaging studies on the self.
Neuroimage 2006;31
(1)
440- 45710.1016/j.neuroimage.2005.12.002
PubMedGoogle Scholar 20.Amodio
DMFrith
CD Meeting of minds: the medial frontal cortex and social cognition.
Nat Rev Neurosci 2006;7
(4)
268- 277
PubMedGoogle Scholar 21.Phillips
MLDrevets
WCRauch
SLLane
R Neurobiology of emotion perception, I: the neural basis of normal emotion perception.
Biol Psychiatry 2003;54
(5)
504- 514
PubMedGoogle Scholar 22.Buckner
RLSnyder
AZShannon
BJLaRossa
GSachs
RFotenos
AFSheline
YIKlunk
W EMathis
CAMorris
JCMintun
MA Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
J Neurosci 2005;25
(34)
7709- 7717
PubMedGoogle Scholar 23.Alexander
GEChen
KPietrini
PRapoport
SIReiman
EM Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies.
Am J Psychiatry 2002;159
(5)
738- 745
PubMedGoogle Scholar 24.Reiman
EMCaselli
RJYun
LSChen
KBandy
DMinoshima
SThibodeau
SNOsborne
D Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E.
N Engl J Med 1996;334
(12)
752- 758
PubMedGoogle Scholar 25.Scahill
RISchott
JMStevens
JMRossor
MNFox
NC Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.
Proc Natl Acad Sci U S A 2002;99
(7)
4703- 4707
PubMedGoogle Scholar 26.Price
JCKlunk
WELopresti
BJLu
XHoge
JAZiolko
SKHolt
DPMeltzer
CCDeKosky
STMathis
CA Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.
J Cereb Blood Flow Metab 2005;25
(11)
1528- 1547
PubMedGoogle Scholar 27.Lustig
CSnyder
AZBhakta
MO’Brien
KCMcAvoy
MRaichle
MEMorris
JCBuckner
RL Functional deactivations: change with age and dementia of the Alzheimer type [published online ahead of print November 7, 2003].
Proc Natl Acad Sci U S A 2003;100
(24)
14504- 1450910.1073/pnas.2235925100
PubMedGoogle Scholar 28.Greicius
MDSrivastava
GReiss
ALMenon
V Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI [published online ahead of print March 15, 2004].
Proc Natl Acad Sci U S A 2004;101
(13)
4637- 464210.1073/pnas.0308627101
PubMedGoogle Scholar 29.Barrett
AMEslinger
PJBallentine
NHHeilman
KM Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects.
Neurology 2005;64
(4)
693- 699
PubMedGoogle Scholar 30.Schmitz
TWJohnson
SC Self-appraisal decisions evoke dissociated dorsal-ventral aMPFC networks [published online ahead of print December 2, 2005].
Neuroimage 2006;30
(3)
1050- 105810.1016/j.neuroimage.2005.10.030
PubMedGoogle Scholar 31.Johnson
SCBaxter
LCWilder
LSPipe
JGHeiserman
JEPrigatano
GP Neural correlates of self-reflection.
Brain 2002;125
(pt 8)
1808- 1814
PubMedGoogle Scholar 32.Schmitz
TWKawahara-Baccus
TNJohnson
SC Metacognitive evaluation, self-relevance, and the right prefrontal cortex.
Neuroimage 2004;22
(2)
941- 947
PubMedGoogle Scholar 33.Sager
MAHermann
BLa Rue
A Middle-aged children of persons with Alzheimer's disease:
APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.
J Geriatr Psychiatry Neurol 2005;18
(4)
245- 249
PubMedGoogle Scholar 34.Ries
MLJabbar
BSchmitz
TWTrivedi
MAGleason
CECarlsson
CMRowley
HAAsthana
SJohnson
SC Anosognosia in mild cognitive impairment: relationship to activation of cortical midline structures involved in self-appraisal.
J Int Neuropsychol Soc 2007;13
(3)
450- 461
PubMedGoogle Scholar 35.Jezzard
PBalaban
RS Correction for geometric distortion in echo planar images from Bo field variations.
Magn Reson Med 1995;34
(1)
65- 73
PubMedGoogle Scholar 36.Jenkinson
M Fast, automated, N-dimensional phase-unwrapping algorithm.
Magn Reson Med 2003;49
(1)
193- 197
PubMedGoogle Scholar 37.Friston
KJ Commentary and opinion, II: statistical parametric mapping: ontology and current issues.
J Cereb Blood Flow Metab 1995;15
(3)
361- 370
PubMedGoogle Scholar 38.Trivedi
MWichmann
AJabbar
BWard
MASchmitz
TWRies
MLKoscik
RLAsthana
SJohnson
SC Structural MRI discriminates individuals with mild cognitive impairment from age-matched controls: a combined neuropsychological and voxel based morphometry study.
Alzheimers Dement 2007;2296- 302
Google Scholar 39.Good
CDJohnsrude
ISAshburner
JHenson
RNFriston
KJFrackowiak
RS A voxel-based morphometric study of ageing in 465 normal adult human brains.
Neuroimage 2001;14
(1, pt 1)
21- 36
PubMedGoogle Scholar 40.Vogt
BAVogt
LLaureys
S Cytology and functionally correlated circuits of human posterior cingulate areas [published online ahead of print September 6, 2005].
Neuroimage 2006;29
(2)
452- 46610.1016/j.neuroimage.2005.07.048
PubMedGoogle Scholar 41.Valenstein
EBowers
DVerfaellie
MHeilman
KMDay
AWatson
RT Retrosplenial amnesia.
Brain 1987;110
(pt 6)
1631- 1646
PubMedGoogle Scholar 42.Wagner
ADShannon
BJKahn
IBuckner
RL Parietal lobe contributions to episodic memory retrieval.
Trends Cogn Sci 2005;9
(9)
445- 453
PubMedGoogle Scholar 43.Johnson
SCSchmitz
TWKawahara-Baccus
TNRowley
HAAlexander
ALLee
JDavidson
RJ The cerebral response during subjective choice with and without self-reference.
J Cogn Neurosci 2005;17
(12)
1897- 1906
PubMedGoogle Scholar 44.Kelley
WMMacrae
CNWyland
CLCaglar
SInati
SHeatherton
TF Finding the self? an event-related fMRI study.
J Cogn Neurosci 2002;14
(5)
785- 794
PubMedGoogle Scholar 45.Lane
RDFink
GRChau
PMDolan
RJ Neural activation during selective attention to subjective emotional responses.
Neuroreport 1997;8
(18)
3969- 3972
PubMedGoogle Scholar 46.Gusnard
DAAkbudak
EShulman
GLRaichle
ME Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function.
Proc Natl Acad Sci U S A 2001;98
(7)
4259- 4264
PubMedGoogle Scholar 47.Nestor
PJFryer
TDIkeda
MHodges
JR Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease).
Eur J Neurosci 2003;18
(9)
2663- 2667
PubMedGoogle Scholar 48.Johnson
NAJahng
GHWeiner
MWMiller
BLChui
HCJagust
WJGorno-Tempini
MLSchuff
N Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.
Radiology 2005;234
(3)
851- 859
PubMedGoogle Scholar 49.Chételat
GDesgranges
BDe La Sayette
VViader
FEustache
FBaron
JC Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
Neurology 2003;60
(8)
1374- 1377
PubMedGoogle Scholar 50.Huang
CWahlund
LOSvensson
LWinblad
BJulin
P Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment.
BMC Neurol 2002;2
(1)
e9
Google Scholar 51.Kogure
DMatsuda
HOhnishi
TAsada
TUno
MKunihiro
TNakano
STakasaki
M Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.
J Nucl Med 2000;41
(7)
1155- 1162
PubMedGoogle Scholar 52.Arikuni
TSako
HMurata
A Ipsilateral connections of the anterior cingulate cortex with the frontal and medial temporal cortices in the macaque monkey.
Neurosci Res 1994;21
(1)
19- 39
PubMedGoogle Scholar 53.Cavada
CCo
TTejedor
JCruz-Rizzolo
RJReinoso-Suarez
F The anatomical connections of the macaque monkey orbitofrontal cortex: a review.
Cereb Cortex 2000;10
(3)
220- 242
PubMedGoogle Scholar 54.Marshall
GAKaufer
DILopez
OLRao
GRHamilton
RLDeKosky
ST Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's disease.
J Neurol Neurosurg Psychiatry 2004;75
(10)
1396- 1400
PubMedGoogle Scholar 55.Mondadori
CRde Quervain
DJBuchmann
AMustovic
HWollmer
MASchmidt
CFBoesiger
PHock
CNitsch
RMPapassotiropoulos
AHenke
K Better memory and neural efficiency in young apolipoprotein E ε4 carriers [published online ahead of print October 31, 2006].
Cereb Cortex 2007;17
(8)
1934- 194710.1093/cercor/bhl103
PubMedGoogle Scholar 56.Handley
OJMorrison
CMMiles
CBayer
AJ
ApoE gene and familial risk of Alzheimer's disease as predictors of odour identification in older adults.
Neurobiol Aging 2006;27
(10)
1425- 1430
PubMedGoogle Scholar 57.Mondadori
CRBuchmann
AMustovic
HSchmidt
CFBoesiger
PNitsch
RMHock
CStreffer
JHenke
K Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years [published online ahead of print September 29, 2006].
Brain 2006;129
(pt 11)
2908- 292210.1093/brain/awl266
PubMedGoogle Scholar 58.Han
SDHouston
WSJak
AJEyler
LTNagel
BJFleisher
ASBrown
GGCorey-Bloom
JSalmon
DPThal
LJBondi
MW Verbal paired-associate learning by
APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response [published online ahead of print January 24, 2006].
Neurobiol Aging 2007;28
(2)
238- 24710.1016/j.neurobiolaging.2005.12.013
PubMedGoogle Scholar 59.Bookheimer
SYStrojwas
MHCohen
MSSaunders
AMPericak-Vance
MAMazziotta
JCSmall
GW Patterns of brain activation in people at risk for Alzheimer's disease.
N Engl J Med 2000;343
(7)
450- 456
PubMedGoogle Scholar 60.Dickerson
BCSalat
DHBates
JFAtiya
MKilliany
RJGreve
DNDale
AMStern
CEBlacker
DAlbert
MSSperling
RA Medial temporal lobe function and structure in mild cognitive impairment.
Ann Neurol 2004;56
(1)
27- 35
PubMedGoogle Scholar 61.Celone
KACalhoun
VDDickerson
BCAtri
AChua
EFMiller
SLDePeau
KRentz
DMSelkoe
DJBlacker
DAlbert
MSSperling
RA Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis.
J Neurosci 2006;26
(40)
10222- 10231
PubMedGoogle Scholar 62.Small
SAPerera
GMDeLaPaz
RMayeux
RStern
Y Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease.
Ann Neurol 1999;45
(4)
466- 472
PubMedGoogle Scholar 63.Machulda
MMWard
HABorowski
BGunter
JLCha
RHO’Brien
PCPetersen
RCBoeve
BFKnopman
DTang-Wai
DFIvnik
RJSmith
GETangalos
EGJack
CR Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients.
Neurology 2003;61
(4)
500- 506[published correction appears in
Neurology. 2003;61(8):1164].
PubMedGoogle Scholar 64.Demb
JBDesmond
JEWagner
ADVaidya
CJGlover
GHGabrieli
JD Semantic encoding and retrieval in the left inferior prefrontal cortex: a functional MRI study of task difficulty and process specificity.
J Neurosci 1995;15
(9)
5870- 5878
PubMedGoogle Scholar 65.Rao
SMBandettini
PABinder
JRBobholz
JAHammeke
TAStein
EAHyde
JS Relationship between finger movement rate and functional magnetic resonance signal change in human primary motor cortex.
J Cereb Blood Flow Metab 1996;16
(6)
1250- 1254
PubMedGoogle Scholar 66.Stark
CESquire
LR When zero is not zero: the problem of ambiguous baseline conditions in fMRI [published online ahead of print October 9, 2001].
Proc Natl Acad Sci U S A 2001;98
(22)
12760- 1276610.1073/pnas.221462998
PubMedGoogle Scholar 67.Morcom
AMFletcher
PC Does the brain have a baseline? why we should be resisting a rest [published online ahead of print October 16, 2006].
Neuroimage 2006;
PubMedGoogle Scholar 68.Sandstrom
CKKrishnan
SSlavin
MJTran
TTDoraiswamy
PMPetrella
JR Hippocampal atrophy confounds template-based functional MR imaging measures of hippocampal activation in patients with mild cognitive impairment.
AJNR Am J Neuroradiol 2006;27
(8)
1622- 1627
PubMedGoogle Scholar